Immix Biopharma, Inc
11150 W. Olympic Boulevard
Los Angeles
California
90064
United States
Tel: 1-888-958-1084
Website: http://immixbio.com/
Email: info@immixbio.com
About Immix Biopharma, Inc
Immix Biopharma, Inc. is a privately held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The team was founded by Vladimir Torchilin, Ph.D., D.Sc. Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University and the former Head of Chemistry Program at Harvard Medical School and Massachusetts General Hospital; Ilya Rachman, an MD, PhD, MBA, physician scientist and clinical researcher; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney and fund manager.YEAR FOUNDED:
2012
LEADERSHIP:
Founders: Ilya Rachman, Sean Senn, and Vladimir Torchilin
CEO: Ilya Rachman
CLINICAL TRIAL:
Please click here for clinical trial information.
86 articles about Immix Biopharma, Inc
-
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
3/20/2024
Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”) today announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial.
-
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness InitiativeHear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words
3/5/2024
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, announced its new AL Amyloidosis awareness campaign Be Proactive in AL™.
-
Immix Biopharma 12 Month Review Progress Update
2/21/2024
Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter.
-
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
2/8/2024
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced the closing of its previously announced underwritten public offering of 5,535,055 shares of its common stock.
-
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
2/7/2024
Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that the European Commission (EC) has granted orphan drug designation to NXC-201 for the treatment of AL Amyloidosis.
-
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
2/6/2024
Immix Biopharma, Inc. announced that it has priced an underwritten public offering of 5,535,055 shares of its common stock at an offering price of $2.71 per share of common stock.
-
Immix Biopharma Announces Proposed Public Offering of Common Stock - February 05, 2024
2/5/2024
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
-
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
1/24/2024
Immix Biopharma, Inc. today announced a statement on January 2024, FDA labeling change notifications for approved CAR-T products.
-
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
1/4/2024
Immix Biopharma, Inc., announced that effective , Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.
-
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
12/18/2023
Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”), announced that effective today, Marko Radic PhD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.
-
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
12/11/2023
Immix Biopharma, Inc today announced new clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study of novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, in patients with relapsed/refractory AL Amyloidosis (R/R ALA) at an oral presentation by study investigator Moshe E. Gatt, MD at the 65th American Society of Hematology (ASH) Meeting being held in San Diego, CA
-
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
11/30/2023
Immix Biopharma, Inc. today announced that it will present and host institutional investor meetings at the 2023 JMP Securities Hematology and Oncology Summit.
-
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL AmyloidosisVirtual Event to be held on November 29, 2023 at 4:15 p.m. ET
11/22/2023
Immix Biopharma, Inc. today announced that it will host a virtual KOL event to discuss its BCMA-Targeted CAR-T cell therapy candidate NXC-201.
-
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
11/21/2023
Immix Biopharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for BCMA CAR-T NXC-201 (formerly HBI0101).
-
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
11/6/2023
Immix Biopharma, Inc. today announced that additional NXC-201 clinical data in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.
-
Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
11/6/2023
Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.
-
Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
10/26/2023
Immix Biopharma, Inc., announced that effective , Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.
-
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
10/16/2023
Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site.
-
Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting
10/3/2023
Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), today announced presentation of additional AL Amyloidosis clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study of novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, at an oral presentation at the 20th International Myeloma Society Annual (IMS) Meeting being held in Athens, Greece on September 27-30 2023,
-
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
10/2/2023
Immix Biopharma Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 (NCT04720313) study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201.